Samsung Biologics highlights faster drug manufacturing timelines at BPI Boston
Samsung Biologics showcased manufacturing technologies designed to accelerate biopharmaceutical development and improve product quality at BioProcess International (BPI) 2026 in Boston, highlighting efforts to streamline complex drug production. The company said Monday it participated in BPI from Sept. 22-25, drawing more than 3,000 biopharmaceutical professionals from around the world. Samsung…
Samsung Biologics highlighted advancements in biopharmaceutical manufacturing at the BioProcess International (BPI) 2026 conference in Boston, emphasizing its commitment to reducing drug production timelines and enhancing product quality. The South Korean company, which has attended the BPI event for nine consecutive years, participated in the exhibition from September 22 to 25, attracting over 3,000 biopharmaceutical professionals from various parts of the globe.
At its dedicated booth, Samsung Biologics showcased its comprehensive capabilities in contract research, development, and manufacturing, as well as its unique Samsung Organoids technology. This technology supports contract development and manufacturing services and production across multiple modalities.
During a Wednesday presentation, Samsung Biologics' team focusing on antibody purification process development unveiled an integrated chemistry, manufacturing, and controls strategy tailored for bispecific and multispecific antibodies. The team explained that their molecule-specific process development approach successfully cut the drug development timeline down from 13 months to 9.5 months, all while preserving high-quality standards.
Scientific posters also showcased various aspects of Samsung Biologics' innovative strategies at the conference.
Written by urgent.news from The Korea Times's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
